HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
BIOBOARD - EUROPE
Bone Therapeutics and Erasme University Hospital start Phase IIa trial in osteoporosis
Bone Therapeutics, an international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases, announced that its partner, the Rheumatology Department of Erasme University Hospital (Brussels, Belgium), has initiated a Phase IIa trial with its lead bone cell therapy product PREOB® for the treatment of severe osteoporosis patients who do not respond to pharmacological treatment. 

PREOB® is Bone Therapeutics’ first-in-class autologous osteoblastic (bone forming) cell therapy product.  Due to its unique mechanism of action, PREOB® could have a significant role to play in the treatment of severe osteoporosis, where the majority of current treatments do not provide bone forming/anabolic activity as their mechanism of action and where over 40% of patients under treatment are still losing bone mass and fracture PREOB® is currently in two pivotal Phase III trials for the treatment of osteonecrosis and non-union fractures. 

This Phase IIa study is a six month open-label trial enrolling 20 patients with severe osteoporosis who do not respond to anti-osteoporotic treatment. PREOB® will be administered via a single intravenous infusion, and the primary endpoints of the trial will be cell body distribution and bone markers. The trial is the first of its kind to be initiated globally and will be run at the Erasme University Hospital (Free University of Brussels (ULB), Belgium).

Bone Therapeutics has been granted from the Free University of Brussels an exclusive worldwide license for PREOB® currently in Phase III clinical trials. Bone Therapeutics was founded in 2006 based on the pioneering works carried out at Erasme University Hospital-ULB, Brussels, Belgium. The Company still maintains close collaborations with scientific experts from various universities such as Prof. Gangji who is now head of the Rheumatology Department of the ULB Erasme Hospital.

Osteoporosis is a disease causing bone fragility and weakness and affects over 200 million people worldwide. Due to aging populations and growing awareness of the disease, the global market for osteoporosis therapeutics is expected to reach $8.8 billion in 2015.

Enrico Bastianelli, Chief Executive Officer of Bone Therapeutics, commented: “We are delighted to be expanding the potential of our lead product PREOB® to osteoporosis, a large disease area with significant unmet need, under the existing agreement that we have with the Free University of Brussels.”

Valérie Gangji, Head of Rheumatology, Erasme University Hospital commented: “We are very excited to be investigating the potential of PREOB® in treatment-resistant osteoporosis, where PREOB®’s unique mechanism of action could have a real impact on patients.  A new treatment such as PREOB® that could reduce the risk of fracture and the formation of new bone could significantly improve the quality of life of these osteoporotic patients.”

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy